Antiviral therapy of hepatitis C with 1 genotype after liver transplantation
Цирульникова О. М., Умрик Д. В.
Вестник трансплантологии и искусственных органов
Т. 20, Вып. 3, С. 105-115
Опубликовано: 2018
Тип ресурса: Обзор
DOI:10.15825/1995-1191-2018-3-105-115
Аннотация:
Chronic HCV infection is the leading cause of liver transplantation in adults in developed countries. Unfortunately, the reinfection of the graft inevitably occurs in all patients with persistent replication of the virus. Against the background of the necessary immunosuppressive therapy, the progression of the disease accelerates, leading to rapid decompensation of the liver. Antiviral therapy significantly improves the results of transplantation, but the use of standard interferon-based regimens is associated with low efficacy (no more than 30[%] for the most common 1 genotype of the virus) and poor tolerance. The article describes new interferon-free oral regimens used to treat the recurrence of HCV infection of 1 genotype. © 2018 Russian Transplant Society. All rights reserved.
Ключевые слова:
Chronic hepatitis C; Direct antiviral action; Liver transplantation; Relapse; Resistant virologic response
Язык текста: Русский
ISSN: 2412-6160
Цирульникова О. М. Ольга Мартеновна 1962-
Умрик Д. В.
Tsirul`nikova O. M. Ol`ga Martenovna 1962-
Umrik D. V.
Antiviral therapy of hepatitis C with 1 genotype after liver transplantation
Текст визуальный непосредственный
Вестник трансплантологии и искусственных органов
Федеральный научный центр трансплантологии и искусственных органов им. академика В.И. Шумакова
Т. 20, Вып. 3 С. 105-115
2018
Обзор
Chronic hepatitis C Direct antiviral action Liver transplantation Relapse Resistant virologic response
Chronic HCV infection is the leading cause of liver transplantation in adults in developed countries. Unfortunately, the reinfection of the graft inevitably occurs in all patients with persistent replication of the virus. Against the background of the necessary immunosuppressive therapy, the progression of the disease accelerates, leading to rapid decompensation of the liver. Antiviral therapy significantly improves the results of transplantation, but the use of standard interferon-based regimens is associated with low efficacy (no more than 30[%] for the most common 1 genotype of the virus) and poor tolerance. The article describes new interferon-free oral regimens used to treat the recurrence of HCV infection of 1 genotype. © 2018 Russian Transplant Society. All rights reserved.